Scilex Holding Company Other Operating Activities, Cash Flow Statement
Scilex Holding Company (SCLX) reported Other Operating Activities, Cash Flow Statement of $733.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherOperatingActivitiesCashFlowStatement · last filed 2026-08-14
- Scilex Holding Company other operating activities, cash flow statement for the quarter ending 2026-06-30 was -$881.00K, a 2358.97% decline year-over-year.
- Scilex Holding Company other operating activities, cash flow statement for the quarter ending 2026-03-31 was $1.61M, a 4147.37% increase year-over-year.
- Scilex Holding Company other operating activities, cash flow statement for the quarter ending 2025-12-31 was -$188.00K, a 169.89% decline year-over-year.
- Scilex Holding Company other operating activities, cash flow statement for the quarter ending 2025-09-30 was $98.00K, a 71.09% decline year-over-year.
- Scilex Holding Company other operating activities, cash flow statement for fiscal 2025 was -$13.00K, a 101.97% decline from fiscal 2024.
- Scilex Holding Company other operating activities, cash flow statement for fiscal 2024 was $661.00K, a 1059.65% increase from fiscal 2023.
- Scilex Holding Company other operating activities, cash flow statement for fiscal 2023 was $57.00K.
- Scilex Holding Company other operating activities, cash flow statement for fiscal 2022 was $0.00.
| Period end | Other Operating Activities, Cash Flow Statement 3 month | Other Operating Activities, Cash Flow Statement 6 month | Other Operating Activities, Cash Flow Statement 9 month | Other Operating Activities, Cash Flow Statement 9 month as first filed | Other Operating Activities, Cash Flow Statement 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$881.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $733.00K 10-Q · filed 2026-08-14 | $545.00K derived: sum of 3 quarters · filed 2026-08-14 | $643.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $1.61M 10-Q · filed 2026-05-20 | $1.43M derived: sum of 2 quarters · filed 2026-05-20 | $1.52M derived: sum of 3 quarters · filed 2026-05-20 | $1.56M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | -$188.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | -$90.00K derived: sum of 2 quarters · filed 2026-04-10 | -$51.00K derived: sum of 3 quarters · filed 2026-08-14 | -$13.00K 10-K · filed 2026-04-10 | |
| 2025-09-30 | $98.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $137.00K derived: sum of 2 quarters · filed 2026-08-14 | $175.00K 10-Q · filed 2025-11-14 | $444.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $77.00K 10-Q · filed 2026-08-14 | $346.00K derived: sum of 3 quarters · filed 2026-08-14 | $685.00K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $38.00K 10-Q · filed 2026-05-20 | $307.00K derived: sum of 2 quarters · filed 2026-05-20 | $646.00K derived: sum of 3 quarters · filed 2026-05-20 | $673.00K derived: sum of 4 quarters · filed 2026-05-20 | |
| 2024-12-31 | $269.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $608.00K derived: sum of 2 quarters · filed 2026-04-10 | $635.00K derived: sum of 3 quarters · filed 2026-04-10 | $661.00K 10-K · filed 2026-04-10 | |
| 2024-09-30 | $339.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $366.00K derived: sum of 2 quarters · filed 2025-11-14 | $392.00K 10-Q · filed 2025-11-14 | -$282.00K derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $53.00K 10-Q · filed 2025-08-13 | -$621.00K derived: sum of 3 quarters · filed 2025-08-13 | $130.00K derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $26.00K 10-Q · filed 2025-05-14 | -$648.00K derived: sum of 2 quarters · filed 2025-05-14 | $103.00K derived: sum of 3 quarters · filed 2025-05-14 | $83.00K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | -$674.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $77.00K derived: sum of 2 quarters · filed 2025-03-31 | $57.00K derived: sum of 3 quarters · filed 2025-03-31 | $57.00K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $751.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | $731.00K derived: sum of 2 quarters · filed 2025-01-17 | $731.00K 10-Q · filed 2025-01-17 | -$19.00K 10-Q · filed 2023-11-14 | $731.00K derived: sum of 4 quarters · filed 2025-01-17 |
| 2023-06-30 | -$20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$20.00K 10-Q · filed 2024-08-13 | -$20.00K derived: sum of 3 quarters · filed 2024-08-13 | -$20.00K derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-13 | $0.00 derived: sum of 2 quarters · filed 2024-05-13 | $0.00 derived: sum of 3 quarters · filed 2024-05-13 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $0.00 derived: sum of 2 quarters · filed 2024-03-12 | $0.00 10-K · filed 2024-03-12 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-11 | ||||
| 2021-12-31 | $0.00 10-K · filed 2024-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |